Skip to main content
S 1913 114th Congress Senate Health Administrative law and regulatory procedures Congressional oversight Consumer affairs Department of Health and Human Services Drug trafficking and controlled substances Drug, alcohol, tobacco use Fraud offenses and financial crimes Government studies and investigations Health care coverage and access Health information and medical records Health technology, devices, supplies Medicare Performance measurement Prescription drugs

Stopping Medication Abuse and Protecting Seniors Act of 2015

Introduced: July 30, 2015 See on congress.gov
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 30, 2015
Read twice and referred to the Committee on Finance.
Jul 30, 2015
Introduced in Senate
 Plain-English summary Congressional Research Service

Stopping Medication Abuse and Protecting Seniors Act of 2015

This bill amends title XVIII (Medicare) of the Social Security Act to: (1) authorize a Medicare prescription drug plan (PDP) sponsor to establish a drug management program under which the PDP sponsor may limit an at-risk beneficiary’s access to coverage for frequently abused drugs to include only those drugs that are prescribed by selected prescribers and dispensed by selected pharmacies; and (2) require a PDP sponsor to have in place a utilization management tool to prevent drug abuse.

With respect to a drug management program, a PDP sponsor must: (1) provide specified notice to a beneficiary who has been identified by the Centers for Medicare & Medicaid (CMS) as “at-risk” and consequently enrolled in the program; and (2) in selecting prescribers and dispensers, ensure that the beneficiary continues to have reasonable access to drugs. These determinations shall be subject to expedited reconsideration and appeal. A PDP sponsor must review and consider an at-risk beneficiary’s preferences regarding prescriber and pharmacy selection.

Certain individuals, including those receiving hospice care or residing in a long-term care facility, are exempted from enrollment in a drug management program.

CMS must, for purposes of quality or performance assessments, review and consider complaints received from at-risk beneficiaries regarding lack of access due to their enrollment in a drug management program. In addition, CMS must establish rules and procedures requiring a PDP sponsor to provide specified program data.

What's happening now July 30, 2015

Read twice and referred to the Committee on Finance.

 Committees of jurisdiction 1